Compare PLYX & GSRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLYX | GSRF |
|---|---|---|
| Founded | 2014 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.8M | 294.6M |
| IPO Year | N/A | N/A |
| Metric | PLYX | GSRF |
|---|---|---|
| Price | $5.19 | $10.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 117.1K | 46.1K |
| Earning Date | 05-22-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $184.52 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.20 | $9.96 |
| 52 Week High | $9.18 | $10.10 |
| Indicator | PLYX | GSRF |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 70.13 |
| Support Level | $4.86 | $9.96 |
| Resistance Level | $5.68 | N/A |
| Average True Range (ATR) | 0.59 | 0.00 |
| MACD | -0.11 | 0.00 |
| Stochastic Oscillator | 15.17 | 84.75 |
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
GSR IV Acquisition Corp is a blank check company.